Kunal Mitra Professor, Mechanical and Aerospace Engineering Department Director- Biomedical...
1
Kunal Mitra Professor, Mechanical and Aerospace Engineering Department Director- Biomedical Engineering Program Florida Institute of Technology, Melbourne, Florida 32901 INTRODUCTION MARKET PROBLEM SOLUTION ULTRASHORT PULSED LASER BASED NON-INVASIVE EARLY CANCER DIAGNOSTIC SYSTEM Short Pulse Laser Based Optical Tomography System - world’s first fully software-controlled, desktop-size produced by Raydiance Inc. (a DFJ Company) - ultra-short pulse laser system providing high spatial and temporal resolution - can provide real-time complete 3-D view of the scanned area - displays soft tissue contrast at cellular level based on functional parameters (e.g. blood volume and oxygenation) as well as structural differences Preliminary proof of concept demonstrated in animal model Provisional Patent (April 2006); Full patent filed (March 2007) What if there is a skin cancer (melanoma) and breast cancer diagnostic technique that is painless, more accurate, less expensive, and quick? - Early cancer detection critical - Current testing can be time-consuming, expensive, invasive, and uncomfortable - Currently dermatologists do multiple biopsies to detect a single case of melanoma - Mammography screening can detect abnormal tissue growths in breast but it cannot distinguish between benign and malignant tumors and is less effective for younger women with dense fibrous breasts Non-invasive Real-time Cancer Diagnostics - Less expensive - Eliminate unnecessary costly biopsies - Comfortable - Transportable compared to other imaging techniques - High sensitivity, specificity, and resolution - Fast image turnaround for patients - Reduce the probability of missing lesions especially in the margins compared to biopsies Volume Production Concept Platform Developer Platform Production Version Medical imaging market worth about $15B in 2006; app. 50% of the revenues garnered by the core modalities MRI, CT, x-ray, ultrasound US markets for breast cancer devices to grow from $1.2B in 2006 to $2.7B by 2012 Breast biopsy devices market valued at over $300M in 2006; double digit growth over the next five years More than 10 million skin biopsies are performed annually in US - by far the most common biopsy Optical Tomograph y Biopsy MRI CT PET time 15 mins 4-14 days 45-60 mins 45-60 mins 75-90 mins cost $ $$ $$$ $$ $$$ safety Excellent Poor Good Poor Fair resolutio n Very Good Good Very Good Very Good Good size Excellent Good Poor Fair Fair COMPETITION “A World Without Skin Biopsies” High sensitivity and specificity system expected to yield physiological and morphological information about breast tumor with a safer, simpler, and cheaper manner compared to existing imaging modalities Conducting animal studies for safety and efficacy Product development partnership in place Completion of clinical trials through partnership Patent application filed (2007) SUMMARY 0. 5 0 1 Lase r Detector 0 100 200 300 400 500 600 10 20 30 40 50 0 200 400 600 800 R e fl ec t e d I n t en s i t y ( a. u . ) ANIMAL STUDIES DATA Pixel representation and 3-D distribution of optical signal for live anaesthetized mouse with two mammary tumors
-
Upload
calvin-anderson -
Category
Documents
-
view
215 -
download
3
Transcript of Kunal Mitra Professor, Mechanical and Aerospace Engineering Department Director- Biomedical...
Kunal MitraProfessor, Mechanical and Aerospace Engineering Department
Director- Biomedical Engineering ProgramFlorida Institute of Technology, Melbourne, Florida 32901
INTRODUCTION
MARKETPROBLEM
SOLUTION
ULTRASHORT PULSED LASER BASED NON-INVASIVE EARLY CANCER DIAGNOSTIC SYSTEM
Short Pulse Laser Based Optical Tomography System - world’s first fully software-controlled, desktop-size produced by Raydiance Inc. (a DFJ Company) - ultra-short pulse laser system providing high spatial and temporal resolution - can provide real-time complete 3-D view of the scanned area - displays soft tissue contrast at cellular level based on functional parameters (e.g. blood volume and oxygenation) as well as structural differences
· Preliminary proof of concept demonstrated in animal model
· Provisional Patent (April 2006); Full patent filed (March 2007)
What if there is a skin cancer (melanoma) and breast cancer diagnostic technique that is painless, more accurate, less expensive, and quick?
- Early cancer detection critical - Current testing can be time-consuming, expensive, invasive, and uncomfortable - Currently dermatologists do multiple biopsies to detect a single case of melanoma - Mammography screening can detect abnormal tissue growths in breast but it cannot distinguish between benign and malignant tumors and is less effective for younger women with dense fibrous breasts
Non-invasive Real-time Cancer Diagnostics - Less expensive - Eliminate unnecessary costly biopsies - Comfortable - Transportable compared to other imaging techniques - High sensitivity, specificity, and resolution - Fast image turnaround for patients - Reduce the probability of missing lesions especially in the margins compared to biopsies
VolumeProduction
Concept Platform Developer Platform Production Version
Medical imaging market worth about $15B in 2006; app. 50% of the revenues garnered by the core
modalities MRI, CT, x-ray, ultrasound
US markets for breast cancer devices to grow from $1.2B in 2006 to $2.7B by 2012
Breast biopsy devices market valued at over $300M in 2006; double digit growth over the next five years
More than 10 million skin biopsies are performed annually in US - by far the most common biopsy
Optical Tomography
Biopsy MRI CT PET
time 15 mins 4-14 days 45-60 mins
45-60 mins
75-90 mins
cost $ $$ $$$ $$ $$$
safety Excellent Poor Good Poor Fair
resolution Very Good Good Very Good Very Good Good
size Excellent Good Poor Fair Fair
COMPETITION
“A World Without Skin Biopsies”
High sensitivity and specificity system expected to yield
physiological and morphological information about breast tumor
with a safer, simpler, and cheaper manner compared to existing
imaging modalities
Conducting animal studies for safety and efficacy
Product development partnership in place
Completion of clinical trials through partnership
Patent application filed (2007)
SUMMARY
0.5
0
1
LaserDetector
0
100
200
300
400
500
600
1020
3040
50 0
200
400
600
800
Ref
lect
ed I
nten
sity
(a.
u.)
ANIMAL STUDIES DATA
Pixel representation and 3-D distribution of optical signal for live anaesthetized
mouse with two mammary tumors
